Related Experiment Video
Updated: May 17, 2026
Continuous Theta Burst Stimulation of the Posterior Medial Frontal Cortex to Experimentally Reduce Ideological Threat Responses
Published on: September 28, 2018
Effects of Experimental Intermittent Theta Burst Stimulation on Negative Symptoms of Schizophrenia: A Double-Blind
Nand Kumar1,2,3, Shiv Prasad4, M V Padma Srivastava5
1Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Abstract:
Background: Negative symptoms remain among the most debilitating and treatment-resistant features of schizophrenia. Repetitive transcranial magnetic stimulation, particularly intermittent theta burst stimulation (iTBS), is emerging as a promising intervention targeting these domains.
Abstract:
Objective: This study aimed to evaluate the efficacy of experimental iTBS applied to the left dorsolateral prefrontal cortex (DLPFC) in ameliorating negative symptoms in patients with schizophrenia.
Abstract:
Methods: In a double-blind, randomized, sham-controlled design, patients with schizophrenia (active group = 71) received daily sessions of experimental iTBS or sham stimulation (sham group = 70) over the left DLPFC for 3 weeks. Clinical outcomes were assessed using the Scale for the Assessment of Negative Symptoms, with a focus on the negative subscale. Patients were diagnosed based on ICD-10 clinical criteria.
Abstract:
Results: Compared to sham, active experimental iTBS did not result in statistically significant improvements in negative symptoms at posttreatment or follow-up. However, the results indicate that experimental iTBS is a safe and well-tolerated intervention with minor adverse effects.
Abstract:
Conclusions: Consistent with several recent large-scale trials and meta-analyses, the findings suggest limited efficacy of experimental iTBS over the left DLPFC for negative symptoms. Future research may investigate alternative stimulation targets, protocols, or combined interventions to enhance treatment outcomes in this population.
Abstract:
Trial Registration: Clinical Trial Registry-India (CTRI) identifier: CTRI/2019/05 019099.
